Short answer
Gilead Sciences (GILD) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 1.01 (Entry into a Material Definitive Agreement). Gilead acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, implying up to $120.00 total consideration per Arcellx share.
Gilead Sciences 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Gilead acquiring Arcellx at $115.00/share cash + $5.00 CVR per share, implying up to $120.00 total consideration per Arcellx share
- CVR milestone: $5.00 payment contingent on anito-cel cumulative global sales exceeding $6B by December 31, 2029; high bar, meaningful execution risk
- Tender offer structure via wholly owned sub Ravens Sub, Inc.; requires >50% share tender plus HSR antitrust clearance to close
- Breakup fee: $260M payable by Arcellx to Gilead if Company walks to accept a Superior Offer; ~2.2% of deal at $115/share base
- Insider support locked up: directors, executives, NEA, and SR One; collectively ~10.3% of shares, already committed to tender
Item 7.01 · Regulation FD Disclosure
- Gilead pursuing full acquisition of Arcellx via tender offer: deal not yet commenced, SEC filings pending
- Key asset: anito-cel (CAR-T therapy), with active BLA under FDA review and a PDUFA date already set
- Transaction expected to be accretive to Gilead following FDA approval; CVR included, tied to milestone achievement
- Closing risks include regulatory approval, Arcellx shareholder tender participation, and potential competing bids
- Arcellx stockholders urged to await formal Schedule TO/14D-9 filings before making any tender decision
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Gilead Sciences 8-K filings
Get the next GILD 8-K as it lands
Follow GILD for push alerts, or ask the research agent what this filing means.